Multiple Myeloma Treatment in India – VRd, ASCT & Daratumumab
Multiple myeloma treatment in India from $10,000. Bortezomib-lenalidomide-dexamethasone (VRd), autologous stem-cell transplant, and daratumumab at expert haematology centres.
Estimated cost: $10,000 – $35,000 · Average stay: 14–45 days
Multiple myeloma is a haematological malignancy of plasma cells causing bone destruction, renal impairment, anaemia, and immune dysfunction. While not currently curable for most patients, modern treatment has transformed it into a manageable chronic condition with significantly prolonged survival — median survival now exceeds 8–10 years with optimal therapy.
India's haematology centres offer the full treatment spectrum: VRd (bortezomib-lenalidomide-dexamethasone) induction, autologous stem-cell transplantation (ASCT), lenalidomide maintenance, and daratumumab-based regimens for relapsed disease — at 80–90% lower cost than the US or UK.
Generic lenalidomide in India costs $150–$400/month versus $20,000+ in the US. Generic bortezomib costs $300–$500/cycle versus $5,000+ in the US — transforming myeloma management from unaffordable to accessible.
What is Multiple Myeloma?
Multiple myeloma arises from clonal plasma cells in the bone marrow that produce excess monoclonal immunoglobulin (M-protein). Diagnosis is established by bone marrow biopsy showing ≥10% clonal plasma cells plus M-protein on serum electrophoresis and/or end-organ damage (CRAB criteria: Calcium elevated, Renal impairment, Anaemia, Bone lesions).
Risk stratification uses the International Staging System (R-ISS) incorporating beta-2-microglobulin, LDH, and high-risk cytogenetics (FISH for del17p, t(4;14), t(14;16)). High-risk cytogenetics determines the intensity of therapy and transplant strategy. Whole-body CT or PET-CT assesses bone disease and plasmacytoma.
Who is Eligible for Myeloma Treatment in India?
All myeloma patients — newly diagnosed or relapsed/refractory — benefit from India's combination of expert haematology-oncology teams and dramatically lower treatment costs. Transplant-eligible patients under 70 with active myeloma can proceed with VRd induction and ASCT. Transplant-ineligible patients receive novel agent-based therapy. International patients seeking access to affordable daratumumab, carfilzomib, or lenalidomide maintenance — unaffordable in many countries — particularly benefit from treatment in India.
How is Multiple Myeloma Treated?
Transplant-eligible patients (generally under 65–70 with good performance status) receive 3–4 cycles of VRd induction (bortezomib subcutaneous + lenalidomide oral + dexamethasone), followed by peripheral blood stem-cell collection via apheresis, then high-dose melphalan conditioning and autologous SCT. Post-transplant lenalidomide maintenance continues until progression.
Transplant-ineligible patients receive 8–12 cycles of VRd or Rd. Daratumumab is now incorporated into frontline therapy for eligible patients. Relapsed/refractory myeloma is treated with daratumumab-Rd (DRd), carfilzomib-Rd (KRd), or ixazomib-containing combinations. MRD (minimal residual disease) assessment guides treatment depth and maintenance decisions.
Procedure Steps
- Diagnostic panel: bone marrow biopsy, SPEP, IFE, sFLC, β2-microglobulin, calcium, creatinine
- Staging by ISS or R-ISS; FISH for del17p, t(4;14), t(14;16) high-risk cytogenetics
- Whole-body CT or PET-CT for bone disease and plasmacytoma assessment
- VRd induction: 3–4 cycles — bortezomib SC, lenalidomide oral, dexamethasone (21-day cycles)
- Response assessment after 2–4 cycles: VGPR, CR, or sCR targeted
- PBSC mobilisation: G-CSF ± plerixafor; apheresis harvest targeting ≥4×10⁶ CD34+ cells/kg
- High-dose melphalan conditioning (200mg/m²); autologous stem-cell infusion
- Engraftment support: G-CSF, infection prophylaxis (aciclovir, fluconazole, IVIG)
- Day +100 response and MRD assessment: bone marrow, SPEP/IFE, PET-CT
- Lenalidomide maintenance 10–15mg/day until progression or intolerance
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $10,000 – $35,000 — Save 94%
UAE — $80,000 – $200,000 — Save 82%
United States — $200,000 – $600,000 — —
United Kingdom — $100,000 – $300,000 — —
VRd induction costs $3,000–$5,000 per cycle in India vs $20,000+ in the US. Generic lenalidomide costs $150–$400/month vs $20,000+ in the US. ASCT adds $18,000–$30,000. Daratumumab is available at 60–70% discount. India provides transformative savings for the entire myeloma treatment journey.
Recovery & Follow-up
VRd induction is largely outpatient — patients maintain reasonable quality of life between cycles. ASCT requires 3–4 weeks of hospital stay, followed by 4–6 weeks nearby before flying home. Fatigue and infection risk are highest in the first 3 months post-ASCT. Most patients return to normal activities within 3–4 months.
Recovery Tips
- Take lenalidomide maintenance at the same time each day; use thromboprophylaxis (aspirin or LMWH) as prescribed.
- Monitor for peripheral neuropathy from bortezomib — report any tingling or numbness immediately for dose adjustment.
- Avoid sick contacts for 3–6 months post-ASCT; wear masks in crowded public spaces.
- Attend all SPEP, sFLC, and bone marrow MRD monitoring appointments as scheduled.
- Annual bone density assessment is recommended — zoledronic acid infusions protect against skeletal events.
Risks & Complications
Bortezomib causes peripheral neuropathy (25–30%), managed by dose reduction. Lenalidomide causes myelosuppression and thromboembolism risk (aspirin prophylaxis is standard). ASCT carries risks of mucositis, infection, and engraftment failure. Daratumumab causes infusion reactions (pre-medication prevents most). Long-term immunosuppression from chronic lenalidomide increases infection risk.
Why GAF Healthcare
Gaf Healthcare coordinates pre-travel staging investigations, priority haematology consultations, ASCT scheduling, accommodation near the transplant centre, and a detailed discharge protocol for continuation of lenalidomide maintenance and monitoring in the patient's home country.
Frequently Asked Questions
Is multiple myeloma curable?
Most patients achieve remission but not complete cure with current therapies. A small subset with standard-risk disease achieve durable remission approaching functional cure. Median survival has improved from 3–4 years to 8–10+ years with modern treatment.
Who is eligible for autologous SCT for myeloma?
Patients under 65–70 (or older with good performance status), without severe organ dysfunction, who achieve at least partial remission with induction are eligible. Age alone is not a contraindication.
Are daratumumab and carfilzomib available in India?
Yes. Daratumumab, carfilzomib, ixazomib, and pomalidomide are available in India — many as generics or at significant discounts versus the US and UK.
How long does myeloma treatment take in India?
VRd induction takes 3–4 months. ASCT adds 3–4 weeks inpatient. International patients typically complete induction and ASCT in India, then continue maintenance at home with remote monitoring.
How does Gaf Healthcare support myeloma patients?
We coordinate pre-travel staging, priority appointments, ASCT scheduling, accommodation near the transplant centre, and a discharge protocol for continuation of maintenance therapy in your home country.